clinical trial · NCT05579730
Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis
Allergic ConjunctivitisBrimonidine tartrate 0.025%/ketotifen fumarate 0.035%Brimonidine Tartrate 0.025%Ketotifen Fumarate 0.035%Vehicle
brief summary
To evaluate the efficacy of Combo (Drug Product Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution) compared to its individual components and vehicle in a population of subjects with allergic conjunctivitis:
started
Oct 12, 2022
primary completion
Jul 22, 2023
completion
Jul 22, 2023
last updated
Feb 14, 2025
official title
Evaluation of Combination Drug Product Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution Compared to Its Components and Vehicle for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge Model
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol